{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:55:54Z","timestamp":1792122954875,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12325-025-03207-6","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T03:35:49Z","timestamp":1748489749000},"page":"3437-3454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer"],"prefix":"10.1007","volume":"42","author":[{"given":"Mehmet A.","family":"Bilen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lowentritt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Khilfeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Kinkead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorie","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"2","key":"3207_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40487-020-00119-z","volume":"8","author":"K Ng","year":"2020","unstructured":"Ng K, Smith S, Shamash J. Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting. Oncol Ther. 2020;8(2):209\u201330. https:\/\/doi.org\/10.1007\/s40487-020-00119-z.","journal-title":"Oncol Ther"},{"issue":"9","key":"3207_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11864-019-0668-8","volume":"20","author":"AB Weiner","year":"2019","unstructured":"Weiner AB, Nettey OS, Morgans AK. Management of metastatic hormone-sensitive prostate cancer (mHSPC): an evolving treatment paradigm. Curr Treat Options Oncol. 2019;20(9):69. https:\/\/doi.org\/10.1007\/s11864-019-0668-8.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"3207_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1903307.","journal-title":"N Engl J Med"},{"issue":"20","key":"3207_CR4","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase\u00a0III TITAN study. J Clin Oncol. 2021;39(20):2294\u2013303. https:\/\/doi.org\/10.1200\/JCO.20.03488.","journal-title":"J Clin Oncol"},{"key":"3207_CR5","unstructured":"FDA approves apalutamide for metastatic castration-sensitive prostate cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-apalutamide-metastatic-castration-sensitive-prostate-cancer."},{"issue":"32","key":"3207_CR6","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase\u00a0III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974\u201386. https:\/\/doi.org\/10.1200\/JCO.19.00799.","journal-title":"J Clin Oncol"},{"issue":"15","key":"3207_CR7","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(15):1616\u201322. https:\/\/doi.org\/10.1200\/JCO.22.00193.","journal-title":"J Clin Oncol"},{"key":"3207_CR8","unstructured":"US Food and Drug Administration. FDA approves enzalutamide for metastatic castration-sensitive prostate cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-enzalutamide-metastatic-castration-sensitive-prostate-cancer. Accessed 29 July 2024."},{"issue":"2","key":"3207_CR9","first-page":"29","volume":"23","author":"B Lowentritt","year":"2024","unstructured":"Lowentritt B, Khilfeh I, Pilon D, et al. Real-world comparison of deep prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer treated with apalutamide or enzalutamide. Rev Urol. 2024;23(2):29\u201340.","journal-title":"Rev Urol"},{"issue":"5","key":"3207_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","volume":"34","author":"S Chowdhury","year":"2023","unstructured":"Chowdhury S, Bjartell A, Agarwal N, et al. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. Ann Oncol. 2023;34(5):477\u201385. https:\/\/doi.org\/10.1016\/j.annonc.2023.02.009.","journal-title":"Ann Oncol"},{"issue":"2","key":"3207_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.eururo.2021.11.020","volume":"81","author":"F Saad","year":"2022","unstructured":"Saad F, Small EJ, Feng FY, et al. Deep prostate-specific antigen response following addition of apalutamide to ongoing androgen deprivation therapy and long-term clinical benefit in SPARTAN. Eur Urol. 2022;81(2):184\u201392. https:\/\/doi.org\/10.1016\/j.eururo.2021.11.020.","journal-title":"Eur Urol"},{"key":"3207_CR12","doi-asserted-by":"publisher","unstructured":"Hussain MHA, Sternberg CN, Efstathiou E et al. Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the phase\u00a0III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA). J Clin Oncol. 2021;39(6_suppl):94\u201394. https:\/\/doi.org\/10.1200\/JCO.2021.39.6_suppl.94.","DOI":"10.1200\/JCO.2021.39.6_suppl.94"},{"issue":"4","key":"3207_CR13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","volume":"77","author":"N Matsubara","year":"2020","unstructured":"Matsubara N, Chi KN, Ozguroglu M, et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase\u00a03 LATITUDE Study. Eur Urol. 2020;77(4):494\u2013500. https:\/\/doi.org\/10.1016\/j.eururo.2019.11.021.","journal-title":"Eur Urol"},{"key":"3207_CR14","doi-asserted-by":"publisher","unstructured":"Saad F, Hussain MHA, Tombal BF et al. Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase\u00a03 ARASENS trial. J Clin Oncol. 2022;40(16_suppl):5078\u20135078. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.5078.","DOI":"10.1200\/JCO.2022.40.16_suppl.5078"},{"issue":"1","key":"3207_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cpt.2474","volume":"111","author":"CA Purpura","year":"2022","unstructured":"Purpura CA, Garry EM, Honig N, Case A, Rassen JA. The role of real-world evidence in FDA-approved new drug and biologics license applications. Clin Pharmacol Ther. 2022;111(1):135\u201344. https:\/\/doi.org\/10.1002\/cpt.2474.","journal-title":"Clin Pharmacol Ther"},{"key":"3207_CR16","unstructured":"US Food and Drug Administration. Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug. Accessed 29 July 2024."},{"key":"3207_CR17","unstructured":"Komodo Mortality Data Version 23.8 User Guide. Komodo Health Inc."},{"key":"3207_CR18","unstructured":"Dorfman AH, Valliant R. The Hajek Estimator Revisited. American Stat. Ass. Section on Survey Research Methods, Washington, 1997;760\u2013765."},{"issue":"6","key":"3207_CR19","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228\u201334. https:\/\/doi.org\/10.1080\/03610910902859574.","journal-title":"Commun Stat Simul Comput"},{"key":"3207_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14796694.2024.2343647","volume":"2024","author":"BH Lowentritt","year":"2024","unstructured":"Lowentritt BH, Du S, Rossi C, et al. Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamide. Fut Oncol. 2024;2024:1\u20139. https:\/\/doi.org\/10.1080\/14796694.2024.2343647.","journal-title":"Fut Oncol"},{"issue":"2","key":"3207_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1903835.","journal-title":"N Engl J Med"},{"issue":"2","key":"3207_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/03008916221090323","volume":"109","author":"M Santoni","year":"2023","unstructured":"Santoni M, Massari F, Rizzo A, et al. Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis. Tumori. 2023;109(2):157\u201363. https:\/\/doi.org\/10.1177\/03008916221090323.","journal-title":"Tumori"},{"issue":"5","key":"3207_CR23","doi-asserted-by":"publisher","first-page":"253.e1","DOI":"10.1016\/j.urolonc.2023.03.003","volume":"41","author":"B Lowentritt","year":"2023","unstructured":"Lowentritt B, Pilon D, Khilfeh I, et al. Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: a comparison of patients initiated on apalutamide or enzalutamide. Urol Oncol. 2023;41(5):253.e1-253.e9. https:\/\/doi.org\/10.1016\/j.urolonc.2023.03.003.","journal-title":"Urol Oncol"},{"issue":"4","key":"3207_CR24","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","volume":"36","author":"LC Harshman","year":"2018","unstructured":"Harshman LC, Chen YH, Liu G, et al. Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel. J Clin Oncol. 2018;36(4):376\u201382. https:\/\/doi.org\/10.1200\/JCO.2017.75.3921.","journal-title":"J Clin Oncol"},{"issue":"15","key":"3207_CR25","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","volume":"27","author":"M Hussain","year":"2009","unstructured":"Hussain M, Goldman B, Tangen C, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2009;27(15):2450\u20136. https:\/\/doi.org\/10.1200\/JCO.2008.19.9810.","journal-title":"J Clin Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03207-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03207-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03207-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T06:36:32Z","timestamp":1764398192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03207-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3207"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03207-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mehmet A. Bilen has acted as a paid consultant for and\/or as a member of the advisory boards of Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Johnson & Johnson, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen,\u00a0and Sanofi and has received grants to his institution from Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech\/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pfizer for work performed outside of the current study. Benjamin Lowentritt is an employee of Chesapeake Urology and has received consulting fees from Johnson & Johnson, Dendreon, Astellas Pharma, Bayer, AstraZeneca\/MedImmune, Merck, Tolmar, Abbvie, Pfizer, and Myovant Sciences. Ibrahim Khilfeh and, Shawn Du are employees and stockholders of Johnson & Johnson. Lorie Ellis was an employee of Johnson & Johnson at the time the study was conducted. Carmine Rossi, Frederic Kinkead, Lilian Diaz, and Dominic Pilon are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Johnson & Johnson. Neal D. Shore is an employee of the Carolina Urologic Research Center and has received consulting fees from Johnson & Johnson, Bayer, Dendreon, Tolmar, Ferring, Medivation\/Astellas, Amgen, Pfizer, AstraZeneca, Astellas Pharma, AbbVie, Merck, Bristol Myers Squibb\/Sanofi, Exact Imaging, FerGene, InVitae, MDxHealth, Myriad Genetics, Propella Therapeutics, Genzyme, Sanofi, CG Oncology, Genesis Cancer Care, Urogen pharma, Speciality Networks, PeerView, Clarity Pharmaceuticals, Lantheus Medical Imaging, Lilly, Photocure, Telix Pharmaceuticals, AIkido Pharma, Arquer Diagnostics, Asieris Pharmaceuticals, Minomic, Novartis, PlatformQ Health, Promaxo, Protara Therapeutics, Fize Medical, Accord Research, Antev, Aura Biosciences, Bioprotect, and Sumitomo Pharma Oncology. NS has received research funding from AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb\/Pfizer, Boston Scientific, Clovis Oncology, Dendreon, Exact Imaging, Ferring, Foundation Medicine, InVitae, Johnson & Johnson, MDxHealth, Merck, Myovant Sciences, Myriad Genetics, Nymox, Pfizer, Sanofi, Sesen Bio, Tolmar, CG Oncology, DisperSol, FORMA Therapeutics, Guardant Health, Jiangsu Yahong Meditech, Novartis, Pacific Edge, POINT Biopharma, Propella Therapeutics, SeaGen, MT Group, Theralase, Veru, Zenflow, Advantagene, Aragon Pharmaceuticals, Endocyte, Exelixis, FKD Therapies, Genentech, Istari Oncology, Medivation, OncoCellMDx, ORIC Pharmaceuticals, Palette Life Sciences, Plexxikon, RhoVac, Steba Biotech, Urogen pharma, Urotronic, US Biotest, and Vaxiion for work performed outside of the current study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments and considered exempt research under 45 CFR \u00a7 46.104(d)(4) as it involved only the secondary use of data that were de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA), specifically, 45 CFR \u00a7 164.514.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}